These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 29602128

  • 1. Targeted cancer therapy through 17-DMAG as an Hsp90 inhibitor: Overview and current state of the art.
    Mellatyar H, Talaei S, Pilehvar-Soltanahmadi Y, Barzegar A, Akbarzadeh A, Shahabi A, Barekati-Mowahed M, Zarghami N.
    Biomed Pharmacother; 2018 Jun; 102():608-617. PubMed ID: 29602128
    [Abstract] [Full Text] [Related]

  • 2. Spotlight on 17-AAG as an Hsp90 inhibitor for molecular targeted cancer treatment.
    Talaei S, Mellatyar H, Asadi A, Akbarzadeh A, Sheervalilou R, Zarghami N.
    Chem Biol Drug Des; 2019 May; 93(5):760-786. PubMed ID: 30697932
    [Abstract] [Full Text] [Related]

  • 3. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ, Margaritis LH, Voutsinas GE.
    Curr Med Chem; 2007 May; 14(29):3122-38. PubMed ID: 18220746
    [Abstract] [Full Text] [Related]

  • 4. 17-DMAG induces heat shock protein 90 functional impairment in human bladder cancer cells: knocking down the hallmark traits of malignancy.
    Karkoulis PK, Stravopodis DJ, Voutsinas GE.
    Tumour Biol; 2016 May; 37(5):6861-73. PubMed ID: 26662567
    [Abstract] [Full Text] [Related]

  • 5. 17 AAG for HSP90 inhibition in cancer--from bench to bedside.
    Usmani SZ, Bona R, Li Z.
    Curr Mol Med; 2009 Jun; 9(5):654-64. PubMed ID: 19601813
    [Abstract] [Full Text] [Related]

  • 6. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C, Lang SA, Stoeltzing O.
    Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
    [Abstract] [Full Text] [Related]

  • 7. In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines.
    Ghadban T, Jessen A, Reeh M, Dibbern JL, Mahner S, Mueller V, Wellner UF, Güngör C, Izbicki JR, Vashist YK.
    Int J Mol Med; 2016 Oct; 38(4):1296-302. PubMed ID: 27498942
    [Abstract] [Full Text] [Related]

  • 8. Design of novel Geldanamycin analogue hsp90 alpha-inhibitor in silico for breast cancer therapy.
    Mahanta S, Pilla S, Paul S.
    Med Hypotheses; 2013 Sep; 81(3):463-9. PubMed ID: 23860250
    [Abstract] [Full Text] [Related]

  • 9. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).
    Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, Sobue G.
    Ann N Y Acad Sci; 2006 Nov; 1086():21-34. PubMed ID: 17185503
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J, Pham NA, Cao MP, Hedley DW.
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [Abstract] [Full Text] [Related]

  • 11. Heat shock protein 90 inhibitors attenuate inflammatory responses in atherosclerosis.
    Madrigal-Matute J, López-Franco O, Blanco-Colio LM, Muñoz-García B, Ramos-Mozo P, Ortega L, Egido J, Martín-Ventura JL.
    Cardiovasc Res; 2010 May 01; 86(2):330-7. PubMed ID: 20154064
    [Abstract] [Full Text] [Related]

  • 12. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV, Workman P.
    Endocr Relat Cancer; 2006 Dec 01; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [Abstract] [Full Text] [Related]

  • 13. Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells.
    Kurashina R, Ohyashiki JH, Kobayashi C, Hamamura R, Zhang Y, Hirano T, Ohyashiki K.
    Cancer Lett; 2009 Oct 18; 284(1):62-70. PubMed ID: 19464103
    [Abstract] [Full Text] [Related]

  • 14. 17-Dimethylaminoethylamino-17-demethoxygeldanamycin attenuates inflammatory responses in experimental stroke.
    Qi J, Han X, Liu HT, Chen T, Zhang JL, Yang P, Bo SH, Lu XT, Zhang J.
    Biol Pharm Bull; 2014 Oct 18; 37(11):1713-8. PubMed ID: 25366476
    [Abstract] [Full Text] [Related]

  • 15. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
    Babchia N, Calipel A, Mouriaux F, Faussat AM, Mascarelli F.
    Invest Ophthalmol Vis Sci; 2008 Jun 18; 49(6):2348-56. PubMed ID: 18281615
    [Abstract] [Full Text] [Related]

  • 16. Silencing of HSP90 cochaperone AHA1 expression decreases client protein activation and increases cellular sensitivity to the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Holmes JL, Sharp SY, Hobbs S, Workman P.
    Cancer Res; 2008 Feb 15; 68(4):1188-97. PubMed ID: 18281495
    [Abstract] [Full Text] [Related]

  • 17. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T, Keum G, Pae AN.
    Expert Opin Ther Pat; 2013 Aug 15; 23(8):919-43. PubMed ID: 23641970
    [Abstract] [Full Text] [Related]

  • 18. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin.
    Wu X, Wanders A, Wardega P, Tinge B, Gedda L, Bergstrom S, Sooman L, Gullbo J, Bergqvist M, Hesselius P, Lennartsson J, Ekman S.
    Br J Cancer; 2009 Jan 27; 100(2):334-43. PubMed ID: 19142186
    [Abstract] [Full Text] [Related]

  • 19. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator.
    Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E, Thillainathan J, Hollingshead M, Sausville EA, Giavazzi R.
    Clin Cancer Res; 2004 Jul 15; 10(14):4813-21. PubMed ID: 15269157
    [Abstract] [Full Text] [Related]

  • 20. Dimeric ansamycins--a new class of antitumor Hsp90 modulators with prolonged inhibitory activity.
    Zhang H, Yang YC, Zhang L, Fan J, Chung D, Choi D, Grecko R, Timony G, Karjian P, Boehm M, Burrows F.
    Int J Cancer; 2007 Feb 15; 120(4):918-26. PubMed ID: 17131314
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.